HUP0202592A3 - Transdermal delivery of lasofoxifene - Google Patents
Transdermal delivery of lasofoxifeneInfo
- Publication number
- HUP0202592A3 HUP0202592A3 HU0202592A HUP0202592A HUP0202592A3 HU P0202592 A3 HUP0202592 A3 HU P0202592A3 HU 0202592 A HU0202592 A HU 0202592A HU P0202592 A HUP0202592 A HU P0202592A HU P0202592 A3 HUP0202592 A3 HU P0202592A3
- Authority
- HU
- Hungary
- Prior art keywords
- lasofoxifene
- transdermal delivery
- transdermal
- delivery
- Prior art date
Links
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 title 1
- 229960002367 lasofoxifene Drugs 0.000 title 1
- 230000037317 transdermal delivery Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20878900P | 2000-06-01 | 2000-06-01 | |
| PCT/US2001/017567 WO2001091724A2 (en) | 2000-06-01 | 2001-05-31 | Transdermal delivery of lasofoxifene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0202592A2 HUP0202592A2 (hu) | 2002-12-28 |
| HUP0202592A3 true HUP0202592A3 (en) | 2003-07-28 |
Family
ID=22776068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0202592A HUP0202592A3 (en) | 2000-06-01 | 2001-05-31 | Transdermal delivery of lasofoxifene |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20020037311A1 (hu) |
| EP (1) | EP1229909B1 (hu) |
| JP (1) | JP2003534368A (hu) |
| KR (1) | KR100795870B1 (hu) |
| CN (1) | CN1400897A (hu) |
| AT (1) | ATE253910T1 (hu) |
| AU (2) | AU785199B2 (hu) |
| BR (1) | BR0106680A (hu) |
| CA (1) | CA2380769A1 (hu) |
| CZ (1) | CZ2002488A3 (hu) |
| DE (1) | DE60101206T2 (hu) |
| DK (1) | DK1229909T3 (hu) |
| ES (1) | ES2210168T3 (hu) |
| HK (1) | HK1052472A1 (hu) |
| HU (1) | HUP0202592A3 (hu) |
| IL (2) | IL147640A0 (hu) |
| MX (1) | MXPA02001152A (hu) |
| NZ (1) | NZ516582A (hu) |
| PL (1) | PL201222B1 (hu) |
| PT (1) | PT1229909E (hu) |
| RU (1) | RU2328276C2 (hu) |
| TR (1) | TR200400241T4 (hu) |
| WO (1) | WO2001091724A2 (hu) |
| ZA (1) | ZA200200519B (hu) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7564908B2 (en) * | 2004-09-23 | 2009-07-21 | Motorola, Inc. | Method and apparatus for encryption of over-the-air communications in a wireless communication system |
| US7804912B2 (en) * | 2004-09-23 | 2010-09-28 | Motorola, Inc. | Method and apparatus for encryption of over-the-air communications in a wireless communication system |
| FR2905601A1 (fr) * | 2006-09-11 | 2008-03-14 | Innoderm Sarl | Utilisation de derives oleiques comme methode et composition favorisant la penetration cutanee des actifs contenus dans les compositions cosmetiques, pharmaceutiques ou dermatologiques. |
| BRPI0814697B8 (pt) | 2007-07-10 | 2021-05-25 | Agile Therapeutics Inc | dispositivo de liberação de fármacos |
| US20100292660A1 (en) * | 2007-07-10 | 2010-11-18 | Agis Kydonieus | Dermal delivery device with ultrasonic weld |
| US20140378424A1 (en) * | 2011-12-30 | 2014-12-25 | Rosscreening, Inc. | Estrogen receptor modulators for reducing body weight |
| CN103751138A (zh) * | 2013-12-31 | 2014-04-30 | 北京万全德众医药生物技术有限公司 | 一种含酒石酸拉索昔芬的口腔崩解片及其制备方法 |
| CN103830196A (zh) * | 2014-03-14 | 2014-06-04 | 王志刚 | 一种酒石酸拉索昔芬分散片及其制备方法 |
| CN103830207A (zh) * | 2014-03-14 | 2014-06-04 | 崔书豪 | 一种酒石酸拉索昔芬贴膏剂 |
| MX2018000166A (es) | 2015-07-24 | 2018-03-26 | Kimberly Clark Co | Metodos para una mejor administración de agentes activos a tumores. |
| AU2016297832B2 (en) * | 2015-07-24 | 2020-07-16 | Vivasor, Inc. | Methods for lymphatic delivery of active agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0799029A1 (en) * | 1994-12-21 | 1997-10-08 | Theratech, Inc. | Transdermal delivery system with adhesive overlay and peel seal disc |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| IL120265A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| US6034102A (en) * | 1996-11-15 | 2000-03-07 | Pfizer Inc | Atherosclerosis treatment |
| US6203817B1 (en) * | 1997-02-19 | 2001-03-20 | Alza Corporation | Reduction of skin reactions caused by transdermal drug delivery |
| CO5170459A1 (es) * | 1999-06-01 | 2002-06-27 | Pfizer Prod Inc | Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos |
-
2001
- 2001-05-31 NZ NZ516582A patent/NZ516582A/en active IP Right Revival
- 2001-05-31 CZ CZ2002488A patent/CZ2002488A3/cs unknown
- 2001-05-31 AT AT01939751T patent/ATE253910T1/de not_active IP Right Cessation
- 2001-05-31 HU HU0202592A patent/HUP0202592A3/hu unknown
- 2001-05-31 WO PCT/US2001/017567 patent/WO2001091724A2/en not_active Application Discontinuation
- 2001-05-31 PT PT01939751T patent/PT1229909E/pt unknown
- 2001-05-31 ES ES01939751T patent/ES2210168T3/es not_active Expired - Lifetime
- 2001-05-31 RU RU2002105378/15A patent/RU2328276C2/ru not_active IP Right Cessation
- 2001-05-31 AU AU65235/01A patent/AU785199B2/en not_active Ceased
- 2001-05-31 DK DK01939751T patent/DK1229909T3/da active
- 2001-05-31 KR KR1020027001424A patent/KR100795870B1/ko not_active IP Right Cessation
- 2001-05-31 JP JP2001587740A patent/JP2003534368A/ja active Pending
- 2001-05-31 CN CN01801561A patent/CN1400897A/zh active Pending
- 2001-05-31 PL PL354628A patent/PL201222B1/pl not_active IP Right Cessation
- 2001-05-31 CA CA002380769A patent/CA2380769A1/en not_active Abandoned
- 2001-05-31 IL IL14764001A patent/IL147640A0/xx active IP Right Grant
- 2001-05-31 DE DE60101206T patent/DE60101206T2/de not_active Expired - Fee Related
- 2001-05-31 MX MXPA02001152A patent/MXPA02001152A/es unknown
- 2001-05-31 US US09/871,318 patent/US20020037311A1/en not_active Abandoned
- 2001-05-31 BR BR0106680-3A patent/BR0106680A/pt not_active Application Discontinuation
- 2001-05-31 EP EP01939751A patent/EP1229909B1/en not_active Expired - Lifetime
- 2001-05-31 TR TR2004/00241T patent/TR200400241T4/xx unknown
-
2002
- 2002-01-15 IL IL147640A patent/IL147640A/en not_active IP Right Cessation
- 2002-01-21 ZA ZA200200519A patent/ZA200200519B/en unknown
-
2003
- 2003-07-09 HK HK03104920.4A patent/HK1052472A1/zh unknown
-
2007
- 2007-02-01 AU AU2007200426A patent/AU2007200426A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL354628A1 (en) | 2004-02-09 |
| IL147640A0 (en) | 2002-08-14 |
| ES2210168T3 (es) | 2004-07-01 |
| EP1229909B1 (en) | 2003-11-12 |
| CA2380769A1 (en) | 2001-12-06 |
| EP1229909A2 (en) | 2002-08-14 |
| KR100795870B1 (ko) | 2008-01-21 |
| AU6523501A (en) | 2001-12-11 |
| DK1229909T3 (da) | 2004-03-15 |
| ZA200200519B (en) | 2003-04-22 |
| RU2002105378A (ru) | 2003-11-10 |
| DE60101206D1 (de) | 2003-12-18 |
| DE60101206T2 (de) | 2004-09-02 |
| HUP0202592A2 (hu) | 2002-12-28 |
| AU2007200426A1 (en) | 2007-02-22 |
| HK1052472A1 (zh) | 2003-09-19 |
| MXPA02001152A (es) | 2002-08-20 |
| RU2328276C2 (ru) | 2008-07-10 |
| WO2001091724A3 (en) | 2002-05-30 |
| NZ516582A (en) | 2004-08-27 |
| IL147640A (en) | 2007-03-08 |
| US20020037311A1 (en) | 2002-03-28 |
| WO2001091724A2 (en) | 2001-12-06 |
| CN1400897A (zh) | 2003-03-05 |
| KR20030025219A (ko) | 2003-03-28 |
| JP2003534368A (ja) | 2003-11-18 |
| BR0106680A (pt) | 2002-04-30 |
| CZ2002488A3 (cs) | 2002-06-12 |
| PL201222B1 (pl) | 2009-03-31 |
| TR200400241T4 (tr) | 2004-04-21 |
| PT1229909E (pt) | 2004-04-30 |
| AU785199B2 (en) | 2006-11-02 |
| ATE253910T1 (de) | 2003-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1531502A (en) | Composition for the transdermal delivery of fentanyl | |
| EP1296699A4 (en) | THERAPEUTIC AGENTS - III | |
| GB0023983D0 (en) | Therapeutic compounds | |
| GB0008710D0 (en) | Therapeutic compounds | |
| GB0016681D0 (en) | Therapeutic compounds | |
| AU2001275286A1 (en) | Transdermal delivery | |
| EP1280485A4 (en) | TRANSDERMAL STAMP FOR IMPROVED MEDICINE | |
| GB0002386D0 (en) | Therapeutic composition | |
| GB0119012D0 (en) | Transdermal delivery of drugs | |
| HUP0202592A3 (en) | Transdermal delivery of lasofoxifene | |
| IL137559A0 (en) | Transdermal drug delivery system | |
| GB0028583D0 (en) | Therapeutic compounds | |
| IL151922A0 (en) | Transdermal therapeutic system for the delivery of lerisetron | |
| AP2003002783A0 (en) | Medicament containing activted antihtrombin iii | |
| IL152646A0 (en) | Dosage of transdermal delivery systems | |
| GB0018887D0 (en) | Compound and their therapeutic use | |
| GB0013105D0 (en) | Therapeutic compounds | |
| TW437365U (en) | Structure of brewing device | |
| GB0021645D0 (en) | Delivery of substances | |
| IL150334A0 (en) | Transdermal drug delivery system | |
| GB0005550D0 (en) | Therapeutic heterocycles | |
| GB0001615D0 (en) | Therapeutic heterocycles | |
| GB0001624D0 (en) | Therapeutic heterocycles | |
| GB0005551D0 (en) | Therapeutic heterocycles | |
| GB0009775D0 (en) | Drug delivery composition |